Background

Sideroflexin 1 (SFXN1) has been discovered as a novel tumor marker for lung adenocarcinoma, but data on its importance in the development of lung adenocarcinoma is still limited. This study evaluated the correlation between SFXN1 and parameters related to ¹⁸F-flurodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT), and further explored the role of SFXN1 in the value-added and glycolytic processes of LUAD.

Method

The expression and prognostic value of SFXN1 mRNA in LUAD were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data base. Retrospective analysis of ¹⁸F-FDG PET imaging and metabolic parameters in 42 patients to explore the relationship between the expression of SFXN1 and glucose metabolism levels in lung adenocarcinoma and its clinical significance. H1975 cells were selected as the in vitro research object, and the biological effects of SFXN1 on LUAD were further elucidated through Edu proliferation assay, CCK8 activity assay, wound healing experiment, and cell flow cytometry.

Result

SFXN1 is highly expressed in various tumors, including LUAD, and its high expression can serve as an independent predictor of overall survival in lung adenocarcinoma. In addition, the expression of SFXN1 in LUAD was significantly correlated with ¹⁸F-FDG PET/CT parameters: maximum and average standardized uptake values (SUVmax and SUVmean), as well as total lesion glycolysis (TLG) (rho = 0.574, 0.589, and 0.338, p < 0.05), which can predict the expression of SFXN1 with an accuracy of 0.934. In vitro functional experiments have shown that knocking down SFXN1 inhibits the proliferation and migration of LUAD cells, promotes cell apoptosis, and may inhibit tumor activity by regulating the expression of glycolytic related genes SLC2A1, HK2, GPI, ALDOA, GAPDH, ENO1, PKM, and LDHA.

Conclusion

The overexpression of SFXN1 is closely related to FDG uptake, and SFXN1, as a promising prognostic biomarker, may mediate the development of LUAD through the glycolytic pathway.

中文翻译：

---

SFXN1 作为 LUAD 的潜在诊断和预后生物标志物与 18F-FDG 代谢参数相关

背景

Sideroflexin 1 (SFXN1) 已被发现作为肺腺癌的新型肿瘤标志物，但有关其在肺腺癌发展中重要性的数据仍然有限。^{本研究评估了SFXN1与18} F-氟脱氧葡萄糖（¹⁸ F-FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）相关参数的相关性，并进一步探讨了SFXN1在LUAD增值和糖酵解过程中的作用。

方法

使用癌症基因组图谱 (TCGA) 和基因表达综合 (GEO) 数据库分析 LUAD 中 SFXN1 mRNA 的表达和预后价值。回顾性分析42例患者的^~(18) F-FDG PET显像及代谢参数,探讨肺腺癌中SFXN1的表达与糖代谢水平的关系及其临床意义。选择H1975细胞作为体外研究对象，通过Edu增殖实验、CCK8活性实验、伤口愈合实验、细胞流式细胞术进一步阐明SFXN1对LUAD的生物学效应。

结果

SFXN1在包括LUAD在内的多种肿瘤中高表达，其高表达可以作为肺腺癌总体生存的独立预测因子。此外，LUAD 中 SFXN1 的表达与¹⁸ F-FDG PET/CT 参数显着相关：最大和平均标准化摄取值（SUVmax 和 SUVmean），以及总病变糖酵解（TLG）（rho = 0.574、0.589、和 0.338，p < 0.05），可以预测 SFXN1 的表达，准确度为 0.934。体外功能实验表明，敲低SFXN1可抑制LUAD细胞的增殖和迁移，促进细胞凋亡，并可能通过调节糖酵解相关基因SLC2A1、HK2、GPI、ALDOA、GAPDH、ENO1、PKM的表达来抑制肿瘤活性。和LDHA。

结论

SFXN1 的过度表达与 FDG 摄取密切相关，SFXN1 作为一种有前景的预后生物标志物，可能通过糖酵解途径介导 LUAD 的发生。